You are here

BeiGene

The 2 Biggest Casualties From the Celgene-Bristol-Myers Merger (So Far)

The 2 Biggest Casualties From the Celgene-Bristol-Myers Merger (So Far)

Yahoo/Motley Fool

Bristol-Myers Squibb

Flag link:

As Bristol-Myers/Celgene tie up loose ends, BeiGene pockets $150M from PD-1 breakup

As Bristol-Myers/Celgene tie up loose ends, BeiGene pockets $150M from PD-1 breakup

Endpoints

Bristol-Myers Squibb

Flag link:

The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs

The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs

Yahoo/Benzinga

Akero Therapeutics

Dermavant Sciences

Prevail Therapeutics

Stoke Therapeutics

Flag link:

Upcoming events – Crucial data on zanubrutinib and filgotinib approach

Upcoming events – Crucial data on zanubrutinib and filgotinib approach

EP Vantage

Waldenström’s macroglobulinemia

Sjögren’s syndrome

Flag link:

Following key late-stage advances, BeiGene puts down $10M to get some discovery projects rolling at Ambrx

Following key late-stage advances, BeiGene puts down $10M to get some discovery projects rolling at Ambrx

Endpoints

Flag link:

Smaller groups await Bristol-Myers Squelgene fallout

Smaller groups await Bristol-Myers Squelgene fallout

EP Vantage

Bristol-Myers Squibb

Vividion Therapeutics

Skyhawk Therapeutics

Dragonfly Therapeutics

Agios Pharmaceuticals

Jounce Therapeutics

Flag link:

In a first, China’s BeiGene scores FDA ‘breakthrough’ status for BTK inhibitor — potential rival for Imbruvica

In a first, China’s BeiGene scores FDA ‘breakthrough’ status for BTK inhibitor — potential rival for Imbruvica

Endpoints

Flag link:

BMS deal weighs on Celgene partners

BMS deal weighs on Celgene partners

BioCentury

Bristol-Myers Squibb

Flag link:

BeiGene bags Asian rights to Zymeworks’ HER2 bispecifics

BeiGene bags Asian rights to Zymeworks’ HER2 bispecifics

Fierce Biotech

bispecific antibodies

Flag link:

BeiGene Announces Acceptance of its NDA in China for Zanubrutinib in Certain Types of Leukemia and Lymphoma

Flag link:

BeiGene Presents Data on it PARP Inhibitor in Combination With Temozolomide in Solid Tumors

BeiGene Presents Data on it PARP Inhibitor in Combination With Temozolomide in Solid Tumors

CP Wire

Flag link:

BeiGene Presents Data on it PARP Inhibitor in Combination With Temozolomide in Solid Tumors

Flag link:

BeiGene Presents Encouraging Results in Ph I Trial of Tislelizumab in Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors

Flag link:

Hong Kong could become biotech listing hub, says BeiGene boss as Chinese drug maker gears up for US$1 billion flotation

Hong Kong could become biotech listing hub, says BeiGene boss as Chinese drug maker gears up for US$1 billion flotation

South China Morning Post

Flag link:

BeiGene Proposes $800+ Million Offering

BeiGene Proposes $800+ Million Offering

CP Wire

Flag link:

BeiGene Proposes $800+ Million Offering

Flag link:

BeiGene Initiates Ph III Trial of PD-1 Inhibitor Tislelizumab + Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer in China

BeiGene Initiates Ph III Trial of PD-1 Inhibitor Tislelizumab + Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer in China

CP Wire

monoclonal antibodies

Flag link:

BeiGene Initiates Ph III Trial of PD-1 Inhibitor Tislelizumab + Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer in China

checkpoint inhibitors

Flag link:

Number 7? Celgene partner BeiGene joins the crowd with stellar PD-1/L1 data from a pivotal test

Number 7? Celgene partner BeiGene joins the crowd with stellar PD-1/L1 data from a pivotal test

Endpoints

Hodgkin's lymphoma

Flag link:

Pages